Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selnoflast in early Parkinson's disease
NCT05924243Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing RO7486967 Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of Participants with adverse events at 45 days and Change in Columbia-Suicide Severity Rating Scale Scores at 45 days. Started Sep 2022; status: completed.
02
Drugs
selnoflast
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05924243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924243.